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Abstract IncobotulinumtoxinA (Xeomin, NT 201) is a
purified botulinum toxin type A free from accessory
(complexing) proteins. Previous studies evaluated single
sets of incobotulinumtoxinA injections for the treatment of
blepharospasm. Individualized injection intervals and other
potential determinants of efficacy and safety need to be
evaluated in a prospective, longitudinal study. Subjects
with blepharospasm who completed a B20 weeks double-
blind, placebo-controlled main period entered a B69 weeks
open-label extension period (OLEX) and received B5
additional incobotulinumtoxinA treatments at flexible
doses (B50 U per eye) and flexible injection intervals
(minimum of 6 weeks). Outcome measures included Jan-
kovic Rating Scale (JRS) (sumscore, severity subscore and
frequency subscore), Blepharospasm Disability Index, and
adverse events. All 102 subjects who completed the main
period entered the OLEX; 82 subjects completed the study,
56 received the maximum five injections. From each
injection visit to a control visit 6 weeks later, investigator-
rated JRS sumscores and subscores, and patient-rated
Blepharospasm Disability Index were significantly
improved (p B 0.001 for all). All scores were still signifi-
cantly improved at trial termination compared with the first
injection visit (p \ 0.05 for all). The most frequently
reported adverse events were eyelid ptosis (31.4 %) and
dry eye symptoms (17.6 %). The injection interval had no
impact on the incidence of adverse events (post hoc anal-
ysis). No subject developed neutralizing antibodies during
the study. Repeated incobotulinumtoxinA injections,
administered at flexible doses and injection intervals from
6 to 20 weeks according to subjects’ needs, provide sus-
tained efficacy in the treatment of blepharospasm with no
new or unexpected safety risks.
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Introduction
Blepharospasm is a focal dystonia characterized by
excessive involuntary contractions of the muscles sur-
rounding the eyes (Hallett et al. 2008). Patients experience
a reduced quality of life and, in severe cases, can even
suffer from functional blindness (Daly 1997).
Botulinum toxin type A has been successfully used for
the treatment of blepharospasm for more than 20 years (for
review see Truong and Jost 2006), having demonstrated
efficacy in several controlled clinical trials (Jankovic and
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Orman 1987; Jankovic et al. 2011; Roggenka¨mper et al.
2006; Truong et al. 2008). IncobotulinumtoxinA (Xeo-
min; also known by its internal drug code NT 201; Merz
Pharmaceuticals GmbH, Frankfurt am Main, Germany) is a
highly purified, lyophilized botulinum neurotoxin type A
formulation. When isolated from Clostridium botulinum
cultures, botulinum toxin is a protein complex consisting of
the 150 kDa core neurotoxin and accessory (complexing)
proteins (Inoue et al. 1996). As a result of a unique puri-
fication process, incobotulinumtoxinA contains only the
150 kDa neurotoxin, and unlike other botulinum toxin
formulations is free from accessory (complexing) proteins
(Frevert 2009; Frevert 2010; Frevert and Dressler 2010).
IncobotulinumtoxinA has demonstrated efficacy and safety
comparable to onabotulinumtoxinA (Allergan Inc., Irvine,
CA, USA) in the treatment of blepharospasm (Rog-
genka¨mper et al. 2006) and cervical dystonia (Benecke
et al. 2005) when the same unit doses were used.
In a double-blind, randomized, placebo-controlled
study, treatment with incobotulinumtoxinA demonstrated
superiority versus placebo for patients with blepharospasm
(Jankovic et al. 2011). As blepharospasm is a chronic
condition, the investigation of long-term treatment options
is essential. Here, we present data from the open-label
extension period (OLEX) of the placebo-controlled study
to evaluate the safety and efficacy of repeated injections of
incobotulinumtoxinA in the treatment of blepharospasm.
The study design incorporated flexible dosing and flexible
injection intervals to allow tailoring of treatment to the
needs of the individual patients.
Methods
The results of the preceding double-blind, randomized,
parallel-group, placebo-controlled main period (MP; clin-
icaltrials.gov identifier NCT00406367) of the trial have
been reported previously with the corresponding inclusion
and exclusion criteria (Jankovic et al. 2011). The OLEX
had an unblinded, non-controlled design and was con-
ducted at 34 centers in the US and Canada. The responsible
Institutional Review Boards approved the study protocol
and informed consent form; patients provided written
informed consent. The ethical principles outlined in the
Declaration of Helsinki and Good Clinical Practice were
followed. The study was monitored by an independent Data
Safety Monitoring Board.
Subjects
Subjects enrolled in this study had completed the MP, and
had expressed the need for a new injection, confirmed by
the investigator [defined as a Jankovic Rating Scale (JRS)
severity subscore C2]. Prior to the MP, all subjects had
received at least two treatments with onabotulinumtoxinA.
The doses used in these onabotulinumtoxinA injections
were the basis for the dose of incobotulinumtoxinA
administered during the MP (Jankovic et al. 2011), using a
clinical conversion ratio 1:1 between onabotulinumtoxinA
and incobotulinumtoxinA (Roggenka¨mper et al. 2006). Re-
injection during the OLEX was possible from as early as
6 weeks up to the time whenever the patient expressed the
need for a new injection. There were no specific exclusion
criteria for the OLEX.
Treatment
During the OLEX, subjects could receive a maximum of
five incobotulinumtoxinA injections over B49 weeks,
followed by a safety observation period of B20 weeks
(total duration B69 weeks). In standard clinical practice,
the treatment interval is typically restricted to around
12 weeks based on the presumption that this delay will
lessen the chance of antibody formation against botu-
linum toxin. However, this study employed flexibility in
dosing and intervals, enabling investigators to re-inject
based on subjects’ needs. Subjects had to contact the
investigator to request a re-injection; re-injection criteria
included a C6-week injection interval and a JRS severity
subscore C2. Dose, dilution, number of injections, and
injection sites were flexible and tailored to each indi-
vidual subject by the investigator, based on the severity
and frequency of spasms, individual response, and history
of adverse events (AEs) of each subject. The total
maximum dose per injection session was 100 U (50 U
per eye).
Each injection visit was followed by an office visit
6 weeks later when symptoms were assessed. The trial
termination visit (TTV) took place 20 weeks (±3 days)
after the last injection or when the subject asked for a new




Severity and frequency of blepharospasm symptoms were
measured using the JRS, which is scored on a scale 0–8
points (sumscore) and includes two subscores: severity and
frequency, both ranging from 0 to 4 (Jankovic and Orman
1987; Jankovic et al. 2009). JRS scores were assessed at all
visits by trained and certified investigators. Changes in
mean JRS scores from each injection visit to the respective
control visit 6 weeks later, and from the first and the last
injection visit to the TTV, were analyzed.
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Blepharospasm Disability Index
Functional impairment was assessed using the Blepharo-
spasm Disability Index (BSDI), a self-rating scale that
includes six daily activity items (‘‘driving a vehicle’’,
‘‘reading’’, ‘‘watching TV’’, ‘‘shopping’’, ‘‘walking’’,
‘‘doing everyday activities’’) (Roggenka¨mper et al. 2006;
Jankovic et al. 2009). These items were rated on a five-
point scale ranging from 0 (no impairment) to 4 (no longer
possible due to my illness). Patients were permitted to rate
items as ‘‘not applicable’’ (except ‘‘doing everyday activ-
ities’’). The BSDI mean score is the sumscore of all
applicable items, divided by the number of applicable
items. Changes in BSDI mean scores were analyzed from
each injection visit to the respective control visit 6 weeks
later, and from the first and the last injection visit to the
TTV.
Patient Evaluation of Global Response (PEGR)
Subjects described their global response using a nine-point
scale ranging from -4 (very marked worsening) to ?4
(complete abolition of all signs and symptoms) (adapted
from Wissel et al. 2000) at all injection visits (except the
first), and at the TTV.
Safety assessments
Throughout the study, subjects were requested to report
all AEs to the investigator. Additionally, they were asked
specifically at all visits about the occurrence of AEs that
could indicate distant effects from toxin spread, such as
stomach and bowel disturbances, drooping of eyelids,
vision problems, dry mouth, swallowing difficulties,
speech problems, shortness of breath, respiratory infec-
tion, local weakness, facial weakness, and general body
weakness. Physical and neurological examinations were
conducted at the beginning of the OLEX, the third
injection visit, and the TTV. Blood samples for labora-
tory tests and determination of antibodies against botu-
linum toxin were collected at all injection visits and the
TTV. Samples were initially screened for botulinum
neurotoxin antibodies using a fluorescence immunoassay
(FIA); as the FIA cannot discriminate between neutral-
izing and non-neutralizing antibodies, positive FIA
samples were subsequently tested using a mouse hemid-
iaphragm assay (HDA) (Go¨schel et al. 1997; Sesardic
et al. 2004).
Investigators rated the tolerability of incobotulinum-
toxinA at all injection visits (except the first), and at the
TTV, using a four-point scale ranging from 1 (very good)
to 4 (poor), based on patient reports.
Statistical analysis
All efficacy variables were analyzed in the intent-to-treat
(ITT) population (all subjects who were randomized in the
MP and included in the OLEX). Changes in mean JRS
scores and BSDI mean score were analyzed with one-
sample t tests with no replacement of missing data. Safety
analyses were carried out in the evaluable-for-safety (EFS)
population (all subjects who received C1 incobotulinum-
toxinA injection during the OLEX). AEs were encoded
using the Medical Dictionary for Regulatory Activities
(MedDRA), Version 9.1.
In a post hoc analysis, a Chi-square test was used to
compare the overall occurrence of AEs between groups of
patients with different median injection intervals (6 to
B10 weeks, [10 to B12 weeks, [12 to B14 weeks, or
[14 weeks). All statistical analyses were performed using
SAS version 8.2 or later (SAS Institute, Cary, NC, USA).
Results
Subjects
One-hundred and two subjects with blepharospasm com-
pleted the MP and all continued into the OLEX. The first
subject entered the OLEX on December 12, 2006 and the
last subject completed the study on July 14, 2009. Eighty-
two subjects (80.4 %) completed the OLEX; 20 subjects
(19.6 %) discontinued prematurely due to withdrawal of
consent (n = 6), insufficient efficacy (n = 4), protocol
violations (n = 4), loss to follow-up (n = 2), or occurrence
of withdrawal criteria (n = 4), which included eyelid sur-
gery (n = 2), treatment with a different botulinum toxin
type A before the TTV (n = 1), and the need for general
anesthesia (n = 1). For the latter subject, breast cancer was
documented as an additional reason for withdrawal, rep-
resenting the only discontinuation due to an AE; no sub-
jects discontinued due to an adverse drug reaction (ADR).
Of the subjects who discontinued due to insufficient effi-
cacy, two returned to onabotulinumtoxinA injections (after
receiving two and three incobotulinumtoxinA treatments in
the OLEX, respectively), one felt that incobotulinumtox-
inA was effective but that the minimum treatment interval
of 6 weeks was too long, and no further details were
documented for the fourth subject. Baseline characteristics
are shown in Table 1.
All subjects who entered the OLEX received C1
incobotulinumtoxinA injection. The mean [standard devi-
ation (SD)] injection interval during the OLEX was
12.6 (4.5) weeks (median 12 weeks); 94.9 % (392/413)
of re-injections were administered at intervals of C6
to B20 weeks. For the 93 subjects who received C2
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injections, the median injection interval was 6 to
B10 weeks for 22 subjects (23.7 %),[10 to B12 weeks for
30 subjects (32.3 %), [12 to B14 weeks for 23 subjects
(24.7 %), and[14 to 20 weeks for 18 (19.4 % of subjects)
(Table 2). Fifty-six subjects (54.9 %) received all five
injections and 25 subjects (24.5 %) received four injections.
The mean (SD) dose of incobotulinumtoxinA administered
for both eyes ranged from 64.7 (22.4) U at the first injection
visit to 72.7 (22.0) U at the fifth visit; the overall range of
doses was 15.0–100.0 U. The mean duration of the OLEX
was 52.6 weeks (range 6.3–75.0 weeks).
JRS sumscore and subscores
Mean JRS sumscores significantly improved from each
injection visit to the respective control visit 6 weeks later
(p \ 0.001 for all visits; Fig. 1a), with mean (SD) differ-
ences between each control and respective injection visit
ranging from -1.6 (1.8) to -2.4 (2.2). Mean (SD) JRS
sumscores at the injection visits decreased from 5.9 (1.4) at
the first injection visit to 4.9 (1.2) at the fifth injection visit.
Mean (SD) JRS sumscores at control visits ranged from 3.1
(2.0) to 3.4 (2.3). At the TTV, the mean JRS sumscore was
significantly reduced from the first and the last injection
visit (p \ 0.001). The improvement in the JRS sumscore
from the first injection visit to the control visit 6 weeks
later was slightly higher for subjects who had received
incobotulinumtoxinA during the MP compared to subjects
who had received placebo in the MP (-2.5 [2.0] vs. -2.2
[2.7]). However, differences between the two treatment
groups of the MP were not statistically significant at the
end of the OLEX.
The mean JRS severity (Fig. 1b) and frequency (Fig. 1c)
subscores followed a similar pattern to the mean JRS
sumscore, indicating significant improvements between
each injection visit and the respective control visit 6 weeks
later (p \ 0.001 for all injection visits). Both subscores
were significantly reduced from the first and the fifth
injection visit to the TTV (p B 0.002 for all).
Blepharospasm Disability Index
Six weeks after each injection visit, the BSDI mean score
was significantly improved (p B 0.001 for all injection
visits; Fig. 2). Mean (SD) difference in the BSDI mean
score between each control and the respective injection
visit ranged from -0.27 (0.59) to -0.50 (0.67). Improve-
ments from each injection visit to the respective control
visit were significant for each single item score of the BSDI
(p B 0.038 for all). The BSDI mean score was significantly
improved from the first injection visit to the TTV
(p = 0.043).
Table 1 Characteristics of subject population at the OLEX baseline
(ITT population)
Total (n = 102)
Male gender, n (%) 36 (35.3)
Race, n (%)
Asian 6 (5.9)
Black or African American 4 (3.9)
Hispanic or Latino 8 (7.8)
White 84 (82.4)
Mean age, years (SD) 62.2 (10.3)
Mean BMI, kg/m2 (SD)a 28.4 (5.3)
Mean duration since first diagnosis
of blepharospasm, months (SD)b
65.9 (61.1)
Mean estimated duration of blepharospasm,
months (SD)b
106.6 (90.0)
Mean JRS scores (SD)
JRS sumscore 5.9 (1.4)
JRS severity subscore 3.1 (0.8)
JRS frequency subscore 2.8 (0.8)
Mean BSDI (SD) 1.50 (0.83)
Most frequent (C40 subjects) concomitant diseases, n (%)
Dry eye 56 (54.9)
Eyelid ptosis 40 (39.2)
BMI body mass index, BSDI Blepharospasm Disability Index, ITT intent-to-
treat, JRS Jankovic Rating Scale, MP main period, OLEX open-label
extension period, SD standard deviation
a Height to calculate the BMI was assessed at screening for the MP
b At screening for the MP
Table 2 Median injection intervals and incidence of AEs by injec-




Number of subjects in
interval groupa n (%)
Number of subjects
with C1 AEb n (%)
6 to B10 weeks 22 (23.7) 18/22 (81.8)c
[10 to B12 weeks 30 (32.3) 24/30 (80.0)c
[12 to B14 weeks 23 (24.7) 22/23 (95.7)c
[14 to 20 weeks 18 (19.4) 12/18 (66.7)c
All intervals 93 (100) 76/93 (81.7)c
Subjects were actively asked at each visit if they experienced
drooping of the eyelid, problems with vision, dry eyes, dry mouth,
swallowing difficulties, speech problems, shortness of breath, respi-
ratory infection, local weakness, facial weakness, general body
weakness, or stomach or bowel disturbances
AE treatment-emergent adverse event, OLEX open-label extension
period
a Ninety-three subjects received C2 injections and B5 injections in
the OLEX and were included in this analysis
b Seventy-six of these 93 subjects experienced C1 AE during the
OLEX
c A Chi square test did not show significant differences in the overall
occurrence of AEs between the different injection interval groups
(p = 0.1229)
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Patient Evaluation of Global Response
At least a moderate improvement in PEGR (C2 points) was
documented by the majority of subjects for injection cycles
1–4 and at the TTV (71/93 [76.3 %], 67/87 [77.0 %], 63/81
[77.8 %], 43/56 [76.8 %], and 76/96 [79.2 %], respec-
tively). At the end of each injection cycle, between 5.4 and
11.8 % of subjects reported complete abolition of all signs
and symptoms, while 3.3–7.4 % of subjects reported that
their symptoms had worsened.
Adverse events
The most frequently reported AEs were eyelid ptosis and dry
eye symptoms, which occurred in 32 (31.4 %) and 18
(17.6 %) subjects, respectively (Table 3). Frequencies of
ADRs per injection cycle ranged from 7.1 (4/56) to 11.8 %
(12/102) for eyelid ptosis and from 3.6 (2/56) to 6.9 % (7/102)
for dry eye symptoms. In total, 44 subjects (43.1 %) reported
C1 ADR over all five injection visits during the OLEX. Most
ADRs were of mild (39 subjects [38.2 %]) or moderate
(14 subjects [13.7 %]) intensity. Severe ADRs were reported
in four subjects (3.9 %) and included eyelid ptosis in three
subjects (2.9 %) and dry eye symptoms in one subject
(1.0 %). The majority of ADRs was transient and resolved by
the end of the OLEX; 12 subjects (11.8 %) experienced ADRs
that were not yet fully recovered at study termination. The
most common unrecovered ADRs were eyelid ptosis (four
subjects, 3.9 %) and dry eye symptoms (five subjects, 4.9 %);
they were classed as ongoing but stable by the respective
investigators at trial termination. Of note, there appeared to be
no trend towards an increase or decrease in the incidence of
ADRs with repeated injections (data not shown). Ten patients
experienced serious AEs during the OLEX, none of which
were considered to be drug-related by the investigators.
Physical and neurological examinations and laboratory
analyses during the OLEX did not reveal any clinically
relevant changes.
Post-hoc analysis
Table 2 shows the incidence of AEs for the 93 subjects
who received C2 injections stratified into 4 different
injection interval groups. Overall, 76 subjects in this pop-
ulation (81.7 %) experienced at least 1 AE over the dura-
tion of the study. A Chi square test did not show significant
differences in the overall occurrence of AEs between the
different injection interval groups (p = 0.1229).
Neutralizing antibodies
No subject developed neutralizing antibodies, defined by a
positive HDA, to incobotulinumtoxinA during the OLEX.
Global Assessment of Tolerability by investigator
The investigator classified the tolerability of study medi-
cation as ‘‘good’’ or ‘‘very good’’ for 91/93 (97.9 %), 85/87
(97.7 %), 79/81 (97.5 %), 54/56 (96.4 %), and 92/95
(96.8 %) of subjects after injection cycles 1–4 and at the
TTV, respectively.
Discussion
This open-label extension of a randomized, placebo-
controlled, double-blind study with a duration of up to
89 weeks (MP plus OLEX) demonstrates that repeated
injections of incobotulinumtoxinA, administered at flexible
intervals with a minimum of 6 weeks and with flexible
doses of up to 50 U per eye, are efficacious and well tol-
erated in the long-term treatment of blepharospasm. This is
the first randomized trial in which flexible injection inter-
vals were used in registration trials in the evaluation of the
efficacy and safety of botulinum neurotoxin type A.
Six weeks after each injection visit, there were signifi-
cant improvements in the investigator-rated severity and
frequency of blepharospasm symptoms (JRS scores) and
significant reductions in functional impairments assessed
using the patient-rated BSDI, results similar to those of the
MP (Jankovic et al. 2011; Roggenka¨mper et al. 2006).
Over the course of the study, the mean JRS baseline
scores at the injection visits gradually decreased and sig-
nificant improvements were seen from the first and the fifth
injection visit to the TTV. This suggests cumulative and
sustained improvements in subjects treated with incobo-
tulinumtoxinA in this long-term study. Moreover, the
flexible dosing intervals might have allowed patients to
receive a new injection before the treatment effect of the
previous incobotulinumtoxinA injections had completely
waned. The mean treatment effect, as assessed via JRS
scores 6 weeks after each injection visit, remained constant
throughout the OLEX.
The trial design permitted flexible treatment intervals
with a minimum of 6 weeks. Current US Prescribing
Information for onabotulinumtoxinA and incobotulinum-
toxinA (both approved for the treatment of blepharospasm
by the US Food and Drug Administration) recommend a
minimum treatment interval of 12 weeks (Allergan 2011;
Merz Pharmaceuticals GmbH 2011), due to concerns
that shorter intervals could promote the formation of
neutralizing antibodies. However, previous studies with
incobotulinumtoxinA in other indications suggest that
incobotulinumtoxinA with its low foreign protein content
and high specific biological activity is associated with low
immunogenicity (Comella et al. 2011; Kan˜ovsky´ et al.
2009, 2011). These data suggested that flexible injection
IncobotulinumtoxinA efficacy in blepharospasm 1349
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intervals could be applied to allow for treatment individ-
ualization based on the individual patient’s clinical needs.
In the current study, post hoc analysis did not show that the
incidence of AEs differed significantly between subjects
with different median injection intervals, suggesting that
shorter injection intervals are not more likely to be asso-
ciated with safety concerns. However, it should be noted
that patient groups in the post hoc analysis were relatively
8.0














































































TTV    
4.0




























































































































































Fig. 1 Mean JRS sumscore (a),
severity subscore (b), and
frequency subscore (c) at
injection visits, control visits
6 weeks following injection
visits, and the TTV (ITT
population). ITT intent-to-treat,
JRS Jankovic Rating Scale,
TTV trial termination visit
***p \ 0.001, one-sample
t test, for the change from the
injection visit to the respective
control visit 6 weeks later
(calculated only for subjects
who attended both the injection
and the respective control visit).
Error bars represent the
standard deviation. The TTV
took place between 6 and
20 weeks after the last injection
visit
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small. A recent multi-national survey among 136 patients
with CD who received treatment with onabotulinumtoxinA
or abobotulinumtoxinA indicated that 78 % of patients
preferred injection intervals B12 weeks, with 46 % of
patients stating they would prefer injection intervals
B10 weeks (Sethi et al. 2012).
Subjects were specifically questioned about AEs that
would indicate toxin spread, including eyelid ptosis and dry
eye symptoms, which might have prompted a greater level
of reporting. This could have contributed to the seemingly
higher incidence of ptosis and dry eye symptoms in this
study compared to other reports of botulinum toxin treat-
ment effects in blepharospasm, though these studies also
only covered one treatment cycle typically without active
questioning (Jankovic and Orman 1987; Roggenka¨mper
et al. 2006; Truong et al. 2008; Wabbels et al. 2011;
Allergan 2011). Specific questioning allowed us to monitor
for changes in the incidence of ptosis and dry eye symp-
toms during the succeeding treatment cycles. No trend was
noted towards an increase in the incidence of AEs with
repeated incobotulinumtoxinA treatments, indicating that
repeated injections at flexible intervals between 6 and
20 weeks are a viable long-term treatment option for sub-
jects with blepharospasm. The most frequently observed
ADRs, eyelid ptosis and dry eye symptoms, well-known
side effects of all botulinum toxin preparations in this
indication, were transient, similar to published experience
(Allergan 2011; Merz Pharmaceuticals GmbH 2011; Ken-
ney and Jankovic 2008). After each injection cycle,[96 %
of investigators reported that incobotulinumtoxinA was
‘‘well’’ tolerated or ‘‘very well’’ tolerated.
Of note in this study, no subjects developed neutralizing
antibodies, determined by the in vitro HDA (Go¨schel et al.
1997), during the MP (Jankovic et al. 2011) or the OLEX.
This is consistent with other studies of incobotulinumtox-
inA (Kan˜ovsky´ et al. 2009, 2011) and supports accumu-
lating evidence that incobotulinumtoxinA is associated
with low immunogenicity.
In conclusion, this OLEX of a double-blind, placebo-
controlled study demonstrated that repeated injections of
incobotulinumtoxinA at flexible intervals provided sus-
tained efficacy in the long-term treatment of blepharo-
spasm. There were no new or unexpected AEs during this
trial and no subjects discontinued due to an ADR. A post
hoc analysis by injection interval (6–20 weeks) did not
show that the incidence of AEs varied significantly for
patients who received repeated injections with different
median intervals. Further long-term observation of a large















































































Fig. 2 BSDI mean score at
injection visits, control visits
6 weeks following injection




TTV trial termination visit
**p = 0.001, ***p \ 0.001,
one-sample t test for the change
from the injection visit to the
respective control visit 6 weeks
later. Error bars represent the
standard deviation. The TTV
took place between 6 and
20 weeks after the last
injection visit
Table 3 AEs affecting C5 % of subjects over the duration of the
OLEX with B5 injection visits (EFS population)
AE, n (%) Total (n = 102)
Subjects with C1 AE 81 (79.4)
Eyelid ptosisa 32 (31.4)
Dry eyea 18 (17.6)
Nasopharyngitisa 9 (8.8)
Visual disturbancea 8 (7.8)
Upper respiratory tract infectiona 8 (7.8)
Blurred visiona 7 (6.9)
Muscular weaknessa 7 (6.9)
Asthenia 6 (5.9)
Dyspneaa 6 (5.9)
AE treatment-emergent adverse event, EFS evaluable-for-safety,
OLEX open-label extension period
a Denotes an AE of special interest. Subjects were actively asked at
each visit if they experienced drooping of the eyelid, problems with
vision, dry eyes, dry mouth, swallowing difficulties, speech problems,
shortness of breath, respiratory infection, local weakness, facial
weakness, general body weakness, or stomach or bowel disturbances
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fully evaluate the immunogenicity of botulinum toxin
preparations for patients with blepharospasm.
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